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Background
Good information on the harm of a drug is vital to
inform risk-benefit decisions and undertake robust cost
effectiveness analysis. Clinical trials reported in peer-
reviewed articles are not useful for this purpose [1,2].
Regulators require pharmaceutical companies to pro-
duce product information documents (Europe:SmPC,
US:USPI). These documents contain comprehensive and
valuable publicly available information on the known
harm of a drug and have the potential to inform impor-
tant risk-benefit decisions. We reviewed the usefulness
of the data presented and compared the harm profile
reported in documents for brand drugs marketed in
Europe and the US.
Method
Inclusion: Antidepressants/antiepileptic brand drugs
evaluated in randomised trials of neuropathic pain and
marketed in the US and Europe. Documentation was
obtained from the European Medicines Agency and
Food Drug Agency.
Results
Twelve brand drugs with matching SmPC and USPI
were included. The number of harms ranged from 56 to
265 for SmPC and 65 to 425 for USPI (Table 1). On
average the USPI contained 70 more harms than the
SmPC (Figure 1). Large numbers of AEs are collected
during clinical trials, the criterion for selecting harms to
report was seldom clear. Twelve of the 24 documents
did report selection criteria but for 8 of these the cri-
teria varied within the document. Medical terminology
dictionaries are used to code AEs with an aim to stan-
dardised reports. More USPIs than SmPCs specified the
dictionary used (6/12 v 3/12). No matched documents
reported using the same dictionaries.
Discussion
It is expected that the harm profile in the product infor-
mation for the same drug should agree. This study
found a lack of consistency for the same drug based on
the same central data available to the pharmaceutical
company, and demonstrates the overwhelming impact of
using arbitrary rules for reporting and differing diction-
aries to code harm data. This problem can only be
exacerbated across drugs.
The development of CORE harm outcome sets
by drug class would improve the usability of this
information by facilitating comparison of harm pro-
files across drug which would support informed risk-
benefit decisions and allow robust cost effectiveness
analyses.
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Table 1. Summary of number of harms by document
Median # harms reported
(range)
Median # harms reported only in one
document(range)
Median # median # of the same harms reported by both
documents (range)
SmPC 114 (56, 265) 43 (20, 181) 75 (36, 104)
USPI 200 (65, 425) 168 (38, 336)
Figure 1 Number of harms reported by matched document
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